Leaders in Life Science Recruitment

Diversity Policy

 STATEMENT OF POLICY

Equality and Diversity

Talentmark recognises the need to offer a supportive and inclusive environment where everyone can reach their full potential without prejudice and discrimination. Diversity covers age, gender, sexual orientation, disability, religion or belief, marital status, political belief, socio economic background, colour, nationality and ethnic origin. Our policy includes both our internal staff and the candidates we work with on a daily basis.

We understand our responsibility within the law and strive to work beyond legislation to provide an inclusive environment where unfair discrimination is challenged and equality is positively promoted. Our policy is regularly reviewed to ensure it meets the highest industry standards.

Our Staff

Through training, we ensure that all members of staff are familiar with our policy. Management are expected to apply our policy within their own area in relation to appointment, training, appraisal, promotion, discipline and day to day interaction. Career development opportunities are to be communicated to all suitably skilled employees who are given equal access to those opportunities.

Any organisation or individual providing training for Talentmark should request advance information from delegates of any special requirements so that suitable arrangements can be made.


Candidates

In recruitment, our only consideration is that the individual meets, or is likely to meet, the requirements of the position.

Applicants for employment with a complaint relating to non-implementation of the Policy should write to Talentmark's Human Resources Department.

A full copy of our Diversity Policy is available on request from the Talentmark Human Resources department. To request a copy, please contact us.

 

Current Opportunities


Browse

Industry News

FDA panel backs Vivus obesity drug Qnexa
FDA panel backs Vivus obesity drug Qnexa...

FDA moves to ease cancer drug shortages
FDA moves to ease cancer drug shortages...

Alex Gorsky to succeed William Weldon as J&J CEO
Alex Gorsky to succeed William Weldon as J&J CEO...

GSK takes up option to develop two Galapagos compounds
GSK takes up option to develop two Galapagos compounds...

Novartis bags rights to Enanta HCV drug in $440 million deal
Novartis bags rights to Enanta HCV drug in $440 million deal...